Mahboobani Neeraj Ramesh, Chong Wing Ho, Lam Samuel Siu Kei, Siu Jimmy Chi Wai, Tan Chong Boon, Wong Yiu Chung
Department of Radiology, Princess Margaret Hospital, Hong Kong.
Department of Radiology, Tuen Mun Hospital, Hong Kong.
Neurointervention. 2017 Mar;12(1):11-19. doi: 10.5469/neuroint.2017.12.1.11. Epub 2017 Mar 6.
A flow diverter (FD) is an effective treatment option for intracranial aneurysms. The Flow Re-direction Endoluminal Device (FRED) is a relatively new flow diverter with a unique dual-layer design. We report our experience and short-term results with the FRED.
We did a retrospective review of all consecutive cases in which the FRED was used to treat intracranial aneurysms at a single institution from March 2014 till December 2015. Clinical parameters, aneurysm characteristics, technical results and short-term outcomes were reviewed.
Eleven intracranial aneurysms were treated with the FRED in 11 patients. The technical device deployment success rate was 100%. Immediate reduction in intra-aneurysmal flow after deployment was noted in 10 cases. The aneurysm occlusion rate at 6 months was 75%. There was 1 complication of in-stent thrombosis immediately after deployment. There was no side branch occlusion, delayed aneurysm rupture, stroke, or intraparenchymal haemorrhage. There was no neurological deficit, morbidity, or mortality.
The FRED is a new FD. It has shown to be safe and effective in our series. The unique dual-layer design of the device renders it to have technical advantages over other FDs. The 6-month aneurysm occlusion rate and complication profile of FRED are similar to other FDs.
血流导向装置（FD）是治疗颅内动脉瘤的一种有效选择。血流再定向腔内装置（FRED）是一种相对较新的具有独特双层设计的血流导向装置。我们报告使用FRED的经验和短期结果。
我们对2014年3月至2015年12月在单一机构中使用FRED治疗颅内动脉瘤的所有连续病例进行了回顾性研究。回顾了临床参数、动脉瘤特征、技术结果和短期结局。
11例患者的11个颅内动脉瘤接受了FRED治疗。器械植入成功率为100%。10例患者在植入后即刻观察到动脉瘤内血流减少。6个月时动脉瘤闭塞率为75%。植入后立即发生1例支架内血栓形成并发症。未发生分支血管闭塞、动脉瘤延迟破裂、卒中或脑实质内出血。无神经功能缺损、致残或死亡。
FRED是一种新型血流导向装置。在我们的系列研究中，它已显示出安全有效。该装置独特的双层设计使其在技术上优于其他血流导向装置。FRED的6个月动脉瘤闭塞率和并发症情况与其他血流导向装置相似。
